动物造模,银屑病关节炎 z-bo 2020-10-08 339

　　Psoriatic arthritis (PsA) is a chronic inflammatory disease that reduces the patient's mobility and flexibility. It is well known that PsA increases the risk of type 2 diabetes. A new study published in the journal FASEB tested a new type of mouse model that could one day be used to treat human skin conditions, degeneration of joints and intervertebral discs, thereby improving the quality of life of PsA patients. It has improved. To conduct this study, the researchers used two groups of non-obese diabetic (NOD) mice.

　　One group was infected with an adenovirus vector capable of expressing single-chain IL-23 (inflammation-inducing cytokine), and the other group was infected with a control virus. After a single intravenous injection, people infected with the IL-23 virus will produce PsA. The systemic spread of the virus has caused a series of common symptoms in PsA patients, including skin, intervertebral disc herniation and joint diseases. Due to the occurrence of these symptoms, this is the only mouse PsA model. Paulobbins, Professor of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota, said: "This new mouse model represents an excellent model of human PsA that contains most of the symptoms of human diseases. This model can be used for detection and optimization. PsA treatment in PsA patients improves the quality of life. In another surprising discovery, researchers observed that IL-23 does not accelerate the onset of diabetes, but it delays hyperglycemia or hyperglycemia.

　　Dr. Thoru Pederson, editor-in-chief of FASEB magazine, said: "This disease has long required a powerful animal model system. This research is a major improvement."